Proteomika. Biomarcadores para el diagnóstico no invasivo de enfermedades complejas.

  1. Inicio
  2. Publicaciones


Img promonitor

Publicaciones (peer reviewed)

Todos los kits Promonitor cuentan con un sólido respaldo en las principales publicaciones

  1. Fiorino G, Ruiz-Argüello MB, Maguregui A et al.Full intercahgeability in regard to immunogenicity between the infliximab reference biologic and biosimilars CT-P13 and SB2 in inflzmmatory bowel disease. Inflamm Bowel Dis. 2018;24:601-606. 29462398
  2. Balsa A, Sanmarti R, Rosas J et al.Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study. Rheumatology (Oxford). 2018 [Epub ahead of print]. 29365183
  3. Martínez-Estupiñán L, Hernández-Flórez D, Janta I et al.An exploratory study to determine whether infliximab modifies levels of rheumatoid factor and antibodies to cyclic citrullinated peptides in rheumatoid arthritis patients. Clin Exp Rheumatol. 2017 [Epub ahead of print] 28850020
  4. Rosas J, Llinares-Tello F, Senabre-Gallego JM et al.Obesity decreases clinical efficacy and levels of adalimumab in patients with ankylosing spondylitis. Clin Exp Rheumatol. 2017;35:145-148. 27908311
  5. Teresa J, Chamaida PR, Ana MF et al.Predictive Value of Serum Infliximab Levels at Induction Phase in Rheumatoid Arthritis Patients. Open Rheumatol J. 2017;11:75-87. 28761564
  6. Ara-Martín M, Pinto PH, Pascual-Salcedo D et al.Impact of immunogenicity on response to anti-TNF therapy in moderate-to-severe plaque psoriasis: results of the PREDIR study. J Dermatolog Treat. 2017;28:606-612. 28274164
  7. Fiorino G, Correale C, Radice S et al.Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients. Aliment Pharmacol Ther. 2017;46:903-905.29023889
  8. Cordero-Coma M, Calleja-Antolín S, Garzo-García I et al.Adalimumab for Treatment of Noninfectious Uveitis: Immunogenicity and Clinical Relevance of Measuring serum Drug Levels and Antidrug Antibodies. Ophthalmology 2016;123(12):2618-25.27692527
  9. Freeman K, Connock M, Auguste P et al. Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits, TNF-α-Blocker ELISA kits and Promonitor® ELISA kits] versus standard care in patients with Crohn's disease: systematic reviews and economic modelling. Health Technol Assess 2016;20(83):1-288.27845027
  10. Ghia C, Akerkar S, Sabnis S et al. Analytical and clinical evaluation of an immunoassay for estimating immunogenicity of infliximab and etanercept in Indian population. J Assoc Physicians India 2016;64:14-17
  11. Gupta R and Misra R Measuring Anti-drug Antibodies: A Step Towards Optimization of Biologic Therapy. J Assoc Physicians India 2016;64:Editorial
  12. Marini JC, Sendecki J, Cornillie F et al. Comparisons of Serum Infliximab and Antibodies-to-Infliximab Tests Used in Inflammatory Bowel Disease Clinical Trials of Remicade. AAPS J 2016 Sep 6 [Epub ahead of print] 27600137
  13. Elberdín L, Outeda M, Salvador P et al. Positive correlation between etanercept concentration and the decrease in Psoriasis Area and Severity Index scale value. Int J Clin Pharm 2016 Jul 19 [Epub ahead of print] 27436193
  14. Laine J, Jokiranta TS, Eklund KK et al. Cost-effectiveness of routine measuring of serum drug concentrations and anti-drug antibodies in treatment of rheumatoid arthritis patients with TNF-α blockers. Biologics 2016 Apr 1;10:67-73. 27099470
  15. Jani M, Isaacs JD, Morgan AW et al. Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels. Rheumatology (Oxford) 2016 Aug 25. pii: kew299 [Epub ahead of print]. 27565176
  16. Jani M, Gavan S, Chinoy H et al. A microcosting study of immunogenicity and tumour necrosis factor alpha inhibitor drug level tests for therapeutic drug monitoring in clinical practice. Rheumatology (Oxford) 2016 Aug 29. pii: kew292 [Epub ahead of print]. 27576368
  17. Inciarte-Mundo J, Ramírez J, Hernández MV et al. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity. Arthritis Res Ther 2016;18(1):160. 27391315
  18. Almirall M, Gimeno R, Salman-Monte TC et al. Drug levels, immunogenicity and assessment of active sacroiliitis in patients with axial spondyloarthritis under biologic tapering strategy. Rheumatol Int [Epub ahead of print] 2016. 26815206
  19. Guiotto C, Daperno M, Frigerio F et al. Clinical relevance and inter-test reliability of anti-infliximab antibodies and infliximab trough levels in patients with inflammatory bowel disease. Dig Liver Dis 2016;48(2):138-43. 26614644
  20. Ruiz-Arguello MB, Maguregui A, Ruiz Del AA et al. Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars. Ann Rheum Dis 2016. 26965981
  21. Arstikyte I, Kapleryte G, Butrimiene I et al. Influence of Immunogenicity on the Efficacy of Long-Term Treatment with TNF alpha Blockers in Rheumatoid Arthritis and Spondyloarthritis Patients. Biomed Res Int 2015;2015:604872. 26064930
  22. Bandres CS, Salvatierra J, Lopez-Sidro M et al. An examination of the mechanisms involved in secondary clinical failure to adalimumab or etanercept in inflammatory arthropathies. J Clin Rheumatol 2015;21(3):115-9. 25807089
  23. Chen DY, Chen YM, Hsieh TY et al. Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up. Rheumatology (Oxford) 2015. 26324949
  24. Chen DY, Chen YM, Hung WT et al. Immunogenicity, drug trough levels and therapeutic response in patients with rheumatoid arthritis or ankylosing spondylitis after 24-week golimumab treatment. Ann Rheum Dis 2015;74(12):2261-4. 26443609
  25. Elberdin L, Outeda M, Salvador P et al. Infliximab drug and antibody levels in patients with dermatological conditions. Int J Clin Pharm 2015;37(2):320-6. 25612566
  26. Fabris M, Pistis C, Zabotti A et al. The Detection of Anti-adalimumab Antibodies in a Series of Inflammatory Polyarthritis: three ELISA Methods Compared. Drug Metab Lett 2015;9(2):132-7. 26256298
  27. Jani M, Chinoy H, Warren RB et al. Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis. Lancet 2015;385 Suppl 1:S48. 26312870
  28. Llinares-Tello F, Rosas-Gomez de SJ, Senabre-Gallego JM et al. Analytical and clinical evaluation of a new immunoassay for therapeutic drug monitoring of etanercept. Clin Chem Lab Med 2015;53(10):e279-e282. 26021413
  29. Martin S, del Agua AR, Torres N et al. Comparison study of two commercially available methods for the determination of golimumab and anti-golimumab antibody levels in patients with rheumatic diseases. Clin Chem Lab Med 2015;53(11):e297-e299. 25945722
  30. Sanmarti R, Inciarte-Mundo J, Estrada-Alarcon P et al. Towards optimal cut-off trough levels of adalimumab and etanercept for a good therapeutic response in rheumatoid arthritis. Results of the INMUNOREMAR study. Ann Rheum Dis 2015;74:e42. 25805737
  31. Schmitz EM, van de Kerkhof D, Hamann D et al. Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits. Clin Chem Lab Med 2015. 26587745
  32. Valor L, Hernandez-Florez D, de lT, I et al. Agreement in assessment of infliximab and adalimumab levels in rheumatoid arthritis: interlaboratory and interassay comparison. Clin Exp Rheumatol 2015;33(5):617-23. 26316061
  33. Valor L, Hernandez-Florez D, de lT, I et al. Investigating the link between disease activity and infliximab serum levels in rheumatoid arthritis patients. Clin Exp Rheumatol 2015;33(6):805-11. 26314759
  34. Zisapel M, Zisman D, Madar-Balakirski N et al. Prevalence of TNF-alpha blocker immunogenicity in psoriatic arthritis. J Rheumatol 2015;42 (1):73-8. 25399390
  35. Chen DY, Chen YM, Tsai WC et al. Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis. Ann Rheum Dis 2014;74(3):e16. 24442879 
  36. Hernandez-Florez D, Valor L, de lT, I et al. Comparison of two ELISA versions for infliximab serum levels in patients diagnosed with ankylosing spondylitis. Rheumatol Int 2014. 25410014
  37. Llinares-Tello F, Rosas-Gomez de SJ, Senabre-Gallego JM et al. Practical application of acid dissociation in monitoring patients treated with adalimumab. Rheumatol Int 2014;34(12):1701-8. 24816715
  38. Llinares-Tello F, Rosas J, de lT, I et al. Comparative study of both versions of an immunoassay commercialized for therapeutic drug monitoring of adalimumab in rheumatoid arthritis. Reumatol Clin 2014;10(2):105-8. 24035361
  39. Marinari B, Botti E, Bavetta M et al. Detection of adalimumab and anti-adalimumab levels by ELISA: clinical considerations. Drug Dev Res 2014;75 Suppl 1:S11-S14. 25381966
  40. Mazilu D, Opris D, Gainaru C et al. Monitoring drug and antidrug levels: a rational approach in rheumatoid arthritis patients treated with biologic agents who experience inadequate response while being on a stable biologic treatment. Biomed Res Int 2014;2014:702701. 24982902
  41. Rosas J, Llinares-Tello F, de lT, I et al. Clinical relevance of monitoring serum levels of adalimumab in patients with rheumatoid arthritis in daily practice. Clin Exp Rheumatol 2014;32(6):942-8. 25327159
  42. Zamora-Atenza C, Diaz-Torne C, Geli C et al. Adalimumab regulates intracellular TNFalpha production in patients with rheumatoid arthritis. Arthritis Res Ther 2014;16(4):R153. 25037855
  43. Ruiz-Arguello B, del Agua AR, Torres N et al. Comparison study of two commercially available methods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels. Clin Chem Lab Med 2013;51 (12):e287-e289. 23917475
  44. Llinares F, Rosas-Gómez de Salazar J, Senabre-Gallego JM et al. Analytical and clinical evaluation of a new immunoassay for therapeutic drug monitoring of infliximab and adalimumab. Clin Chem Lab Med 2012;50:1845-7. 23089717
  45. Plasencia C, Pascual-Salcedo D, Nuño L et al. Influence of immunogenicity on the efficacy of long-term treatment of spondyloarthritis with infliximab. Ann Rheum Dis 2012;71:1955-60. 22563028
  46. Pascual-Salcedo D, Plasencia C, Ramiro S et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology 2011;50(8):1445-52. 21427177

Promonitor cuenta con mas de 100 abstracts publicados en los principales congresos internacionales